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The role of PLN in SR Ca 2ϩ cycling and cardiomyocyte contractility is well defined, and increased PLN inhibition of SR Ca 2ϩ cycling is a major characteristic of human and experimental heart failure (5) . Furthermore, the identification of human PLN mutations linked to dilated or hypertrophic cardiomyopathy (11, 33) has provided support for the functional significance of PLN activity in the heart. As a consequence, the regulation of SR Ca 2ϩ uptake represents a promising therapeutic target. Characterization of the downstream molecular and electrophysiological cascades associated with PLN modifications is therefore a critical step.
The coding sequence of PLN is highly conserved across species, with the exception of amino acid position 27, where human PLN (hPLN) contains a lysine and mouse (m)PLN contains an asparagine. Notably, expression of the hPLN in the mouse heart was associated with superinhibition of SERCA2a leading to reduced cardiac contractility and hypertrophy yet, ultimately, cardiac remodeling and survival (46) . Therefore, this mouse model represents a valuable means for deciphering the spectrum of molecular and cellular pathways in which hPLN is implicated, and for better understanding the role of SR Ca 2ϩ cycling in cardiac remodeling.
To dissect these processes, the present study utilized global gene expression analysis combined with electrophysiology and mathematical simulations. Our findings reveal significant electrical, structural, and transcriptional remodeling in hPLN mouse hearts and point to the specific molecular players orchestrating these processes. Importantly, the hPLN-induced superinhibition of SERCA2a results in molecular changes that resemble previously described markers of hypertrophy and heart failure only to some extent, while multiple others are new and thus attribute novel roles to hPLN. Deciphering these molecular pathways and associating them with specific electrophysiological adaptations involved in the hPLN mouse phenotype provide insights into the downstream effects of PLN in cardiac function and could ultimately unveil promising new therapeutic targets.
MATERIALS AND METHODS
Tissue specimens. Hearts from male FVB/N mice at 11 wk of age with cardiac-specific expression of the human PLN gene (N27K-PLN) in the PLN-deficient mouse background (mouse lines TGL1 and TGL2) and age-matched wild-type (WT) mice were collected at the University of Cincinnati (46) . WT mice were chosen over PLNdeficient mice with ␣-MHCp-driven mPLN expression since the highest level of mouse PLN expression driven by ␣-MHCp in the null background is only 70% of WT levels.
The ventricles were dissected and snap frozen. Alternatively, ventricular myocytes were dissociated according to a standard protocol. The research protocol was approved by the institutional ethical committee and conformed with the principles outlined in the Declaration of Helsinki (1) Global gene expression analysis by microarrays. The CodeLink Mouse Whole Genome Bioarrays were used according to recommended protocols (GE Healthcare). These arrays contain 35,587 30-mer oligonucleotide probes, representative of 36,142 transcripts, including 300 positive and 320 negative controls, on a three-dimensional surface (7, 36) . The correlation between the biological replicates used in this study was very high, with intragroup (among TGL2 or among WT) correlation coefficient values for probes marked "good" with Ͻ1.5 fold change ranging between 98.4% and 99.5%. Each array successfully passed all the quality thresholds set by the Codelink Expression Analysis software (Bioarray QC metrics), and all the positive and negative controls were within the recommended range.
RNA isolation. Each TGL2 and WT sample was homogenized in TRIzol (Invitrogen) followed by phase separation in chloroform as previously described (31) . Only high-quality total RNA samples were included in the microarray analysis, with 260 nm-to-280 nm absorbance ratios between 1.9 and 2.1 and 28S-to-18S rRNA ratios close to 2, on 1.5% agarose gels. In total 12 samples were used, of which 6 were derived from transgenic and 6 from WT animals.
cRNA target preparation, microarray hybridization, and detection. Initially, 2 g of total RNA from each sample and bacterial control mRNAs were used for single-strand cDNA synthesis starting with a T7 oligo(dT) primer as per GE Healthcare recommendations. Doublestranded cDNA was then synthesized and purified with the QIAquick purification kit (Qiagen) followed by biotin-labeled cRNA synthesis, for 14 h in an air incubator at 37°C, with the CodeLink Expression Assay Reagent Kit (GE Healthcare). Only cRNA samples with sufficient quantity and high quality (260 nm-to-280 nm absorbance ratios between 1.8 and 2.1) were used for the preparation of the hybridization reaction mixtures. The samples were hybridized to Codelink Mouse Whole Genome Bioarrays at 37°C and 300 rpm for 18 h. After hybridization, the bioarrays were washed and stained with Cy5-streptavidin (Amersham). Each bioarray was scanned with a GenePix 4200AL Array Scanner (Axon Instruments) with the laser set at 635 nm, 100% laser power, the photomultiplier tube set at 600 V, and pixel size of 5 m.
Bioinformatic data analysis. The 12 scanned images were initially analyzed with Codelink Expression Analysis v4.2 software for bioarray quality evaluation and data extraction. The resulting mediannormalized data were further processed with GeneSifter (VizX Labs). Specifically, only probes with "good" or "low" signal flags were included in the analysis. These flags are assigned by the Codelink Expression Analysis software to each probe of each hybridized bioarray, based on proprietary algorithms, to indicate quality of signal. Significant gene expression changes between hPLN and WT samples were determined with Student's t-test (2-tailed) on log2-transformed data, with thresholds of P Ͻ 0.01 and fold change Ͼ 1.5. All the raw and normalized data are available at the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the series number GSE20172.
Protein extraction. Cardiac homogenates from WT and transgenic (TGL1 and TGL2) mice were prepared in ice-cold lysis buffer supplemented with protease inhibitor cocktail (Sigma-Aldrich Chemie, Schnelldorf, Germany) and 1 mM PMSF. The Quant-iT protein assay kit (Invitrogen, Eugene, OR) was used to determine protein concentration on a Qubit fluorometer (Invitrogen).
Immunoblotting. SDS-PAGE and immunoblotting analysis were performed, as previously described (12), with one of the following primary antibodies: rabbit polyclonal anti-Scn8a/Nav1.6 (1:200; Sigma-Aldrich Chemie), rabbit polyclonal anti-Kcnd2/Kv4.2 (1:200; SigmaAldrich Chemie), rabbit polyclonal anti-Kcnq1/Kv7.1 (1:200; SigmaAldrich Chemie), and mouse monoclonal anti-GAPDH (1:10,000; Abcam, Cambridge, UK) and a peroxidase-conjugated goat anti-rabbit secondary antibody (3:10,000; Bio-Rad Laboratories, Hercules, CA) or goat anti-mouse (1:14,000; Sigma-Aldrich Chemie).
Electrophysiological recordings. Ventricular myocytes from WT and TGL2 mice were dissociated with standard methods. The action potential, the transient outward current (Ito), the L-type Ca 2ϩ current (ICaL), and the Na ϩ /Ca 2ϩ exchanger (NCX) were recorded with whole cell patch clamp (6, 44) .
Mathematical modeling of mouse ventricular myocytes. Modeling of mouse ventricular myocytes was done with the Physiome CellML Environment (PCEnv v0.4). The model was obtained from the CellML model repository (3). SERCA2a half-saturating constant (i.e., SERCA2a Ca 2ϩ affinity, Km,up) was 0.32 M for WT and 0.5 M for hPLN myocytes based on our previous studies (46) . For the hPLN myocyte model, fast transient outward current (Ito-f) and NCX conductances were decreased by 50% and 40%, respectively, and ICaL conductance was increased by 40%. Simulations were performed at 0.2-ms time resolution and were run for at least 300 s. Longer runs were performed to verify that the results were at steady state.
RESULTS
Molecular pathways implicated in cardiac remodeling of hPLN mice. TGL2 hPLN and WT mouse hearts were analyzed in this study unless otherwise noted. After normalization, filtering, and log2 transformation, the 12 data sets (6 hPLN and 6 WT) were analyzed with GeneSifter software. Significant expression changes (P Ͻ 0.01 and Ͼ1.5 fold change) were identified in 320 different genes and expressed sequence tags (ESTs) (Supplemental Table S1 ): 205 genes were significantly upregulated, with values as high as 34-fold, and 115 genes were significantly downregulated, with values as low as Ϫ6-fold. 1 These observations suggest a considerable change in the variety and levels of expressed transcripts in the left ventricle, in response to the N27K single amino acid change of PLN.
To decipher the biological implications of these changes, Gene Ontology annotations were used to group the significantly changed genes based on the "cellular component," "biological process," and "molecular function" of their corresponding proteins.
At the level of "biological process," Ͼ100 significantly changed genes were involved in protein metabolism (e.g., Prkcb1, Usp53, Map3k6), nucleic acid metabolism (the vast majority of which were transcription related; see below), and signal transduction (e.g., Pde7b, Rgs11, Ctgf). Furthermore, numerous cell differentiation and cell cycle genes (e.g., Wwox, Pten, Tgfb2) were significantly changed. Importantly, Ͼ25 genes were associated with transport and ϳ10 of them with ion transport. The ion transport group of genes included sodium (e.g., Slc5a12, Slc13a4, Scn8a), potassium (e.g., Kcnq1, Kcnd2), calcium (e.g., Prkcb1), and zinc (e.g., Slc39a3) ion transport genes (Fig. 1) .
The Gene Ontology "molecular function" categories presenting with the highest numbers of significantly changed genes were those of protein binding (69 genes), ion binding (37 genes), and nucleic acid binding (28 genes). Consistent with the marked changes in ion transport genes, a large number of ion binding genes were significantly changed, relating to sodium, potassium, calcium, zinc, magnesium (e.g., Fah), copper (e.g., Snai3, Loxl2), and iron (e.g., Cyp1b1) ion binding. Genes associated with transcription included both transcription acti-vators (e.g., Stat3, Nfatc2) and transcription repressors (e.g., Zfhx1b, Aebp2). Overall, 14 transcription factors (e.g., Stat3, Wt1, Ebf1, Fos) and 5 transcription cofactors (Nrip1, Ifi204, Actn2, Ppargc1b, Aebp2) were significantly changed.
Effect of hPLN on cardiac ion transporter protein expression. Western blotting analysis validated microarray findings and showed that the changes in ion channel and transporter protein expressions in the hPLN model agreed well with the changes at the gene expression level (Fig. 2) . Notably, the Scn8a Na ϩ channel subunit was increased by 80% compared with WT, the Slc8a1 (or NCX1) Na ϩ /Ca 2ϩ exchanger was increased by 44%, the K ϩ channel subunit, Kcnd2, was decreased by 40% (while Kcnd3 was unchanged), and the slowly activating delayed rectifier K ϩ current (I Ks ) K ϩ channel subunit, Kcnq1, was increased by 65%. Interestingly, the L-type Ca 2ϩ channel subunit, Cacna1c, was increased by 42% at the protein level, although there was no change at the gene expression level. Selected proteins were further evaluated in the TGL1 hPLN mouse line with similar results (Fig. 3) , consistent with the superinhibitory effects exhibited by PLN mutations at amino acid 27 (N27K and N27A) (32, 45, 46) . In addition, there were no alterations in SERCA, PLN, or calsequestrin protein expression levels in either TGL1 or TGL2 compared with WT controls (data not shown).
Effect of hPLN on cardiac cellular electrophysiological properties. To understand the functional consequences of the observed alterations in ion transporter expression, cellular electrical properties of ventricular myocytes from hPLN hearts were examined with whole cell patch clamp. Compared with WT, hPLN myocytes had prolonged action potential duration (APD) (Fig. 4A) , while the resting potential or action potential height was not changed. The average APD at 60% repolarization (APD 60 ) was prolonged by 65%, from 2.67 ms in WT to 4.42 ms in hPLN myocytes (Fig. 4B) .
The prolongation of APD in hPLN myocytes correlated with a significant reduction of the K ϩ conductance (Fig. 5A) . The peak K ϩ current density measured at ϩ40 mV was reduced from 57 pA/pF in WT to 42 pA/pF in hPLN (P Ͻ 0.01, Fig.  5B ). The K ϩ current in mouse ventricular myocytes has several components with distinct molecular identities (27) . Consistent with the downregulation of Kcnd2, which underlies I to-f , the reduction of total K ϩ conductance in hPLN myocytes was solely the result of decrease in I to-f (Fig. 5C ). I to-f density was reduced by ϳ50% in hPLN myocytes, while the densities of the slow component of I to (I to-s ) and the steady-state current (I ss ) were not changed.
Expression of human PLN also resulted in marked remodeling of the I CaL and the NCX current. Peak I CaL at 0 mV was increased by 39%, a result that agrees with the increase in Cacna1c protein expression (Fig. 2) and our previous findings (46) . Interestingly, despite increases in Slc8a1 at the mRNA and protein levels, there was a 40% decrease in NCX activity in hPLN cells (Fig. 5D) .
Mathematical simulation of hPLN ventricular myocytes:-role of ion transport remodeling. We used a modified mouse ventricular myocyte model (3) to examine the contribution of ion transport changes to the cellular phenotype of the hPLN myocytes. The simulated hPLN action potential had a longer APD compared with WT (Fig. 6A) , and this was largely accounted for by the reduction of I to-f (Fig. 6D) . The prolonged APD and increased I CaL conductance in the hPLN model resulted in increased Ca 2ϩ influx during the action potential (Fig. 6A) . We next compared the Ca 2ϩ dynamics of WT, hPLN, and WT with an increase of SERCA2a K m,up alone without any ion transport remodeling (referred to below as the "K m,up1 model"). Compared with WT, the K m,up1 model showed a dramatic suppression of the peak Ca 2ϩ transient level from 0.51 to 0.29 M and a small increase in the diastolic Ca 2ϩ level (Fig. 6B) . The K m,up1 model also showed marked decrease in both diastolic SR content (from 1.7 to 0.6 mM) and amplitude of triggered SR Ca 2ϩ release (Fig. 6C ). These abnormalities in Ca 2ϩ dynamics were consistent with a decreased SR Ca 2ϩ reuptake as a result of the decreased SERCA2a Ca 2ϩ affinity. Importantly, with the ion transport remodeling incorporated into the model, the hPLN model showed significantly improved Ca 2ϩ dynamics compared with the K m,up1 model. In the hPLN model the Ca 2ϩ transient levels were improved (peak ϭ 0.43 M; Fig. 6B ), SR release was increased, and diastolic SR content was slightly higher (Fig. 6C) .
We next investigated the contribution of individual ion transport changes to the improved Ca 2ϩ dynamics in the hPLN (Fig. 6E) . On the other hand, the increased SR Ca 2ϩ content shown in Fig. 6C was solely a result of the decrease in NCX conductance density (Fig. 6F) .
DISCUSSION
We have determined the specific molecular and electrical changes triggered through superinhibition of mouse SERCA2a by hPLN, thus uncovering new molecular players implicated in the cardiac response to Ca 2ϩ cycling aberrations. The specific pathways contributing to compensation for the mild pathology of hPLN mice are unveiled and discussed.
Cellular electrical remodeling. Alterations in hPLN cardiac gene expression are accompanied by significant changes in ventricular action potential morphology and K ϩ and Ca 2ϩ conductance. Simulation studies show that incorporation of ion transport remodeling in the hPLN model improved SR Ca 2ϩ cycling beyond that under suppressed SERCA2a function alone. The resulting Ca 2ϩ transient amplitude relative to that in WT (Fig. 6B) agreed well with that observed experimentally in our previous findings (46) . These simulation results suggest that the electrical remodeling may serve as a compensatory mechanism that enhances Ca 2ϩ dynamics and attenuates what would otherwise be a more severe pathological phenotype (Fig. 7) .
Among the immediate downstream effects of aberrant Ca 2ϩ homeostasis in the hPLN hearts appear to be alterations in K ϩ and Na ϩ ion transport. Kcnd2 (Kv4.2) expression and I to-f density were reduced. This is in agreement with many, but not all, previous studies demonstrating downregulation of Kcnd and I to-f in cardiac hypertrophy (9, 42) . Decrease of I to-f largely accounts for the moderate prolongation of APD in hPLN cells and results in increase of Ca 2ϩ influx during the action potential. Interestingly, the two major changes in Ca 2ϩ transport, i.e., upregulation of I CaL and downregulation of the NCX, appear to occur at the posttranscriptional/posttranslational levels. The mRNA and protein levels for NCX were increased in hPLN hearts, while a 40% decrease was found at the NCX functional level. Similar upregulation of NCX gene and protein expression and decrease in NCX function have been reported in a compensated pressure-overload cardiac hypertrophy model (41) . Such remodeling of NCX in hypertrophy is in contrast with the situation in heart failure, where upregulation of both NCX protein and function has been consistently observed (37) , and is believed to contribute to impaired excitation-contraction coupling and arrhythmias (2, 28) . Simulation studies suggest that changes in both I CaL and NCX contribute to improved Ca 2ϩ dynamics of the hPLN heart, although the individual effects of NCX downregulation on SR load and Ca 2ϩ transient were fairly minor in the hPLN hearts.
Although the primary defect in the hPLN hearts is the altered structure and function of PLN, with direct implications in Ca 2ϩ homeostasis, there were no major expression changes in Ca Table S1 ). Among them, S100a8 and S100a9, the most downregulated genes in this study (Ϫ4.91-fold and Ϫ6-fold, respectively), have been shown to interact with SERCA2a and affect Ca 2ϩ flux, cardiac contractility, and ejection fraction (4).
Significant increases were also observed in the expression of the voltage-gated Na ϩ channel subunits (Scn8a and Scn9a), while the Prkcb1 underexpression could further promote their function (29, 40) . These channels contribute, at least to some extent, to Na ϩ current (I Na ) in cardiomyocytes (13) . Structural remodeling. Successful function of ion channels and membrane transporters requires tight control of their highly specialized subcellular localization. The significant expression changes in numerous structural genes in the hPLN mice could directly and/or indirectly affect these processes. For example, the actin cytoskeleton (Acta1, ϩ1.81-fold) has been shown to participate in the organization of voltage-gated K ϩ channels through Actn2 (Ϫ1.94-fold) (21) . Furthermore, emerging evidence shows that Actn2 can mediate the direct coupling of Ca 2ϩ and Ca 2ϩ -activated K ϩ channels (21), which could translate into yet another mechanism bridging Ca 2ϩ concentration aberrations with K ϩ changes in hPLN mice. Another example involves syntrophins, actin-binding proteins and components of the dystrophin-associated protein complex, that can bind Na ϩ channels and to a lesser extent K ϩ channels, while the inward rectifier K ϩ channels associate with both syntrophins (Sntg1, ϩ1.55-fold) and Cask (ϩ1.76-fold) (10, 20) . Through these interactions syntrophins and Cask may modulate the anchoring, clustering, and function of ion channels with direct implications in the propagation of depolarization and cardiac function.
In addition to their role in ion channel and membrane transporter localization and function, the multiple structural gene expression changes suggest extensive cytoarchitectural modifications in hPLN hearts. Significant gene expression changes were observed in sarcomeric/contractile (e.g., Myh6, Myom2, Myl1), cytoskeletal (e.g., Gas7, Shroom3, Sntg1), and intercalated disk proteins (Supplemental Table S1 ), suggesting a multilevel structural reorganization (14, 35) . Since Ca 2ϩ directly affects contractility and therefore sarcomere function, changes in Ca 2ϩ dynamics such as those observed in hPLN cardiomyocytes could cause sarcomeric rearrangements that may be related to hypertrophy and/or compensate for the aberrant cardiomyocyte function (Fig. 7) .
Transcriptional remodeling. Approximately 8.5% of the 320 significantly changed genes in the hPLN model were associated with transcription. Importantly, the cytoskeletal membrane scaffold protein Cask (ϩ1.76-fold) demonstrates nuclear translocation and transcriptional regulation, which may be dependent on Ca 2ϩ concentrations in close proximity of the protein (16, 34) . Similarly, Actn2 (Ϫ1.94-fold) has been proposed to work as a primary coactivator for the nuclear receptor family of transcription factors (17) .
Both Cask and Actn2 as well as Ppargc1b (ϩ1.91-fold) have been shown to bind Grip (ϩ3.19-fold), while the latter two also enhance Grip1 transcriptional activity, thus contributing to the cross talk between cytoskeletal organization and transcriptional regulation in cardiomyocytes (17, 19) . Grip1, in turn, is an important coactivator of the Mef2 family of myogenesisrelated transcription factors. Consistent with a pattern of increased myogenesis in the hPLN mouse hearts, the myoblast fusion regulator Nfatc2 (ϩ1.51-fold), as well as its downstream mediator, Il4 (ϩ2.91-fold), were significantly overexpressed, while the negative regulator of myogenesis, Wt1, was significantly underexpressed (Ϫ1.65-fold) (15, 25) . The reduced Stat3 expression (Ϫ1.67-fold) could be contributing to these processes by enabling the switch from myoblast proliferation to differentiation (38) . Ca 2ϩ concentration changes are likely the primary activator of the myogenic machinery, via calcineurin activation of Nfatc2 (26) . The increased myogenesis and muscle growth in hPLN hearts could serve as a compensatory mechanism to facilitate cardiac function (Fig. 7) .
Nfatc2 upregulation could contribute to Tgfb2 upregulation (ϩ1.8-fold), which has been implicated in the development of cardiac hypertrophy (30) . Meantime, Tfgb is also known to negatively regulate the proapoptotic Irf1 (24) . Consistently with this notion, Irf1 was significantly underexpressed, together with the proapoptotic Fos and Wwox (Ϫ1.55-, Ϫ2.73-, and Ϫ1.63-fold, respectively). Furthermore, Fos downregulation appears to contribute to improved left ventricular function in failing hearts after cardiac support device therapy (43) . This evidence points to the inactivation of apoptotic pathways possibly contributing to the absence of a progressive pathological phenotype in hPLN mice (Fig. 7) .
Other remodeling processes. The overexpressed Pten has been shown to promote cardiac contractility (8) , whereas Tgfa, the most upregulated gene (34-fold) in hPLN mice, is likely to play an important, yet to be elucidated, role. Only limited changes were observed in energy metabolism, and there were no major changes in inflammatory response-related genes, further supporting the notion that the combined action of hPLN and the downstream activated pathways gives rise to a relatively mild pathological phenotype.
Study limitations. A limitation of the present study is the use of nontransgenic WT mice instead of ␣-MHC promoter-driven mPLN transgenic mice as controls. Unfortunately, the highest level of mPLN expression, obtained in the knockout hearts, is only 70% of that in WT mice (22) . Thus it was not appropriate to use a model with 70% expression of mPLN to examine the effects elicited by 100% expression of hPLN in the null background. For this reason, WT mice were used as control in our study. In addition, we cannot exclude that some of the observed alterations may be associated with promoter artifacts in the hPLN hearts. However, this is not likely since a second transgenic line (TGL1) exhibited some protein alterations that were similar to those in TGL2.
Conclusions. We demonstrate that hPLN, through superinhibition of SERCA2a, causes significant changes in Ca 2ϩ homeostasis and in turn a series of electrical, structural, and transcriptional remodeling processes (Fig. 7) . A network of interconnected molecular and electrophysiological adaptations appears to promote hypertrophy, myogenesis, cardiac protection, and survival of the transgenic mice in the presence of the superinhibitory hPLN. A clear understanding of this cellular network and the underlying control mechanisms that fine-tune gene expression may be of significant future therapeutic value. 
